Introduction Maternal anti-SARS-CoV-2 Spike antibodies can cross the placenta during pregnancy, and neonates born to infected mothers have acquired antibodies at birth. Few studies reported data on the histopathological changes of the placenta during infection and placental infection. SARS-CoV-2 infection may cause impaired development of the placenta, thus predisposing maternal and fetal unfavorable outcomes. The prospective study aims to evaluate the risk of vertical transmission of SARS-CoV-2 and placental passage of anti-Spike antibodies as well as the impact of clinical severity on placental structures. Methods This is a prospective cohort study on 30 pregnant women infected by SARS-CoV-2 with their neonates. The demographic features and pregnancy outcomes were collected. Gross and microscopic examinations of the placentas were done. Maternal and umbilical cord sera were obtained at the time of delivery. Nasopharyngeal swabs were collected from neonates immediately after birth. Results The concentrations of total anti-SARS-CoV-2 Spike antibodies were higher in pregnant women with moderate to severe/critical disease. The maternal total anti-SARS-CoV-2 Spike levels were correlated with those of neonatal levels. The rate of placental abnormalities is high in the mothers with severe disease, and those with positive anti-SARS-CoV-2 IgM. All neonates had negative nasopharyngeal swabs for SARS- CoV-2 infections and all placentas were negative in immunohistochemical staining for Spike protein. Discussion The maternally derived anti-SARS-CoV-2 Spike antibody can transmit to neonates born to infected mothers regardless of gestational age. Our results indicated that the disease severity is associated with ischemic placental pathology which may result in adverse pregnancy outcomes.

Purpose Coronavirus disease 2019 (COVID‐19) continues to threaten public health globally. Severe acute respiratory coronavirus type 2 (SARS‐CoV‐2) infection‐dependent alterations in the host cell signaling network may unveil potential target proteins and pathways for therapeutic strategies. In this study, we aim to define early severity biomarkers and monitor altered pathways in the course of SARS‐CoV‐2 infection. Experimental Design We systematically analyzed plasma proteomes of COVID‐19 patients from Turkey by using mass spectrometry. Different severity grades (moderate, severe, and critical) and periods of disease (early, inflammatory, and recovery) are monitored. Significant alterations in protein expressions are used to reconstruct the COVID‐19 associated network that was further extended to connect viral and host proteins. Results Across all COVID‐19 patients, 111 differentially expressed proteins were found, of which 28 proteins were unique to our study mainly enriching in immunoglobulin production. By monitoring different severity grades and periods of disease, CLEC3B, MST1, and ITIH2 were identified as potential early predictors of COVID‐19 severity. Most importantly, we extended the COVID‐19 associated network with viral proteins and showed the connectedness of viral proteins with human proteins. The most connected viral protein ORF8, which has a role in immune evasion, targets many host proteins tightly connected to the deregulated human plasma proteins. Conclusions and Clinical Relevance Plasma proteomes from critical patients are intrinsically clustered in a distinct group than severe and moderate patients. Importantly, we did not recover any grouping based on the infection period, suggesting their distinct proteome even in the recovery phase. The new potential early severity markers can be further studied for their value in the clinics to monitor COVID‐19 prognosis. Beyond the list of plasma proteins, our disease‐associated network unravels altered pathways, and the possible therapeutic targets in SARS‐CoV‐2 infection by connecting human and viral proteins. Follow‐up studies on the disease associated network that we propose here will be useful to determine molecular details of viral perturbation and to address how the infection affects human physiology.

Objective: We aimed to describe the infectivity of adult and pediatric COVID-19 patients in the presence of viral shedding and anti-SARS-CoV-2 antibody response. Materials and Methods:A total of 408 consequent samples from eleven adults and five pediatric patients with SARS-CoV-2 infection were included. Reverse transcription-polymerase chain reaction (RT-PCR) and viral culture were performed for the samples obtained every other day from saliva, nasopharynx, feces, serum, urine, and tear. Anti-SARS-CoV-2 antibodies were measured. Results:The median duration of RNA shedding in all specimens was 7 (2-15) days in adults and 5 (3-19) days in children. The median duration from symptom onset to admission was three days. The viral RNA was positive in 44.7 % of the nasopharynx and 37.6% of saliva samples up to 16 days in adults and 19 days in children. We detected the latest viral culture positivity in the nasopharynx on day eight of symptoms. The viral RNA was found in 6.1% of feces, 4.4% of serum, 4.3 % of tear, 2.9% of urine. The earliest seroconversion was the seventh day for adults and the eighth day for children. On the 14th day, total antibody positivity was 78% in adults and 80% in children. After seroconversion, the viral RNA was still detected in the nasopharynx and saliva of three patients; however, the infectious virus was not present. Conclusion:The infectivity of a positive patient is low after eight days of symptoms. The risk of fecal-oral transmission is very low, and strict hand hygiene measures could be preventive.

No abstract

Background: The maintenance of vaginal microbiota is an important factor to achieve ideal pregnancy outcomes. Coronavirus disease has been shown to have potential adverse effects on pregnancy and neonatal outcomes. Pregnancy itself is a risk factor for the severity of COVID-19, with an increased risk of intensive care unit (ICU) admission, maternal morbidity, and mortality. the role of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in vaginal microbiome composition in pregnant women with COVID-19 has not yet been investigated. Therefore, we anticipate that COVID-19 may unfavorably affect the composition of the vaginal microbiota, resulting in adverse pregnancy outcomes. We aimed to describe the alterations of the composition of vaginal microbiota in pregnant women with COVID-19.Results: A prospective case-control study was conducted among 19 pregnant women with COVID-19 and 28 healthy controls matched according to the gestational week and age. The vaginal swabs were collected during the active phase of infection and consecutively, within a month after recovering from infection. In three patients, longitudinal samples before, in the course, and after infection were also obtained. The microbiome alterations were examined by 16S rRNA gene sequencing. We indicated that COVID-19 was associated with vaginal dysbiosis during pregnancy, which was indicated by an increased alpha diversity index. There was a signi cantly decrease in Firmicutes (P=0.007) and Lactobacillus (P=0.019) with an increase in Bacteroidetes (P=0.024) in the COVID-19 group. In the moderate/severe group, increased amounts of Ureaplasma and vanishing of Lactobacillus gasseri were found in women, compared to the asymptomatic or mild group (P=0.001). In longitudinal analysis, elevation of Actinobacteria with reduction of Firmicutes and Bacteroides were indicated during the active phase. Conclusions: The study revealed vaginal dysbiosis with a low abundance of Lactobacillus and an increase in Bacteroidetes in relation to SARS-CoV-2 infection. Vaginal dysbiosis in COVID-19 could be a contributing factor in pregnancy adverse outcomes. Trial registration: clinicaltrials, Registered 15